看似散发性胰腺导管腺癌患者中的有害胚系突变
该研究对2000至2015年在约翰霍普金斯医院接受胰腺切除的854例胰腺导管腺癌患者、288例其他胰腺及壶腹周围肿瘤患者和51例非肿瘤疾病患者正常组织DNA测序32个基因,发现33例(3.9%;95%CI 3.0%至5.8%)胰腺癌患者携带有害胚系突变,其中31例(3.5%)涉及已知家族性胰腺癌易感基因,仅3例报告胰腺癌家族史。
要点
- 854例胰腺癌中33例(3.9%;95%CI 3.0%至5.8%)携带有害胚系突变。
- 31例(3.5%)突变位于已知家族性胰腺癌易感基因,以BRCA2和ATM最常见。
- 33例中仅3例报告胰腺癌家族史,多数无提示遗传性癌症综合征的家族史。
核心结论
- 在无明显癌症家族史的胰腺癌患者中常见胰腺癌易感基因的胚系突变,部分突变具有治疗靶向性;若仅以现行家族史指南作为基因检测指征,这些突变将被遗漏。
研究设计与样本
- 对2000至2015年在约翰霍普金斯医院接受胰腺切除的854例胰腺导管腺癌患者、288例其他胰腺及壶腹周围肿瘤患者和51例非肿瘤疾病患者,取正常组织DNA测序32个基因(包括已知胰腺癌易感基因)。
主要发现
- 854例胰腺癌患者中33例(3.9%;95%CI 3.0%至5.8%)携带有害胚系突变,其中31例(3.5%)涉及已知家族性胰腺癌易感基因:BRCA2 12例、ATM 10例、BRCA1 3例、PALB2 2例、MLH1 2例、CDKN2A 1例、TP53 1例。
- 携带这些胚系突变的患者较未携带者年轻(均值±标准差,60.8±10.6岁 vs 65.1±10.5岁;P=.03)。
- 另发现BUB1B(1例)和BUB3(1例)有害胚系突变。
- 33例中仅3例报告胰腺癌家族史,多数无提示遗传性癌症综合征的癌症家族史。
- 288例其他壶腹周围肿瘤患者中5例(1.7%)携带有害胚系突变。
临床怎么用
- 原文结论指出,若仅以现行家族史指南作为决定基因检测适宜性的主要标准,这些有害胰腺癌易感基因突变将被遗漏。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Deleterious germline mutations contribute to pancreatic cancer susceptibility and are well documented in families in which multiple members have had pancreatic cancer. Methods To define the prevalence of these germline mutations in patients with apparently sporadic pancreatic cancer, we sequenced 32 genes, including known pancreatic cancer susceptibility genes, in DNA prepared from normal tissue obtained from 854 patients with pancreatic ductal adenocarcinoma, 288 patients with other pancreatic and periampullary neoplasms, and 51 patients with non-neoplastic diseases who underwent pancreatic resection at Johns Hopkins Hospital between 2000 and 2015. Results Thirty-three (3.9%; 95% CI, 3.0% to 5.8%) of 854 patients with pancreatic cancer had a deleterious germline mutation, 31 (3.5%) of which affected known familial pancreatic cancer susceptibility genes: BRCA2 (12 patients), ATM (10 patients), BRCA1 (3 patients), PALB2 (2 patients), MLH1 (2 patients), CDKN2A (1 patient), and TP53 (1 patient). Patients with these germline mutations were younger than those without (mean ± SD, 60.8 ± 10.6 v 65.1 ± 10.5 years; P = .03). Deleterious germline mutations were also found in BUB1B (1) and BUB3 (1). Only three of these 33 patients had reported a family history of pancreatic cancer, and most did not have a cancer family history to suggest an inherited cancer syndrome. Five (1.7%) of 288 patients with other periampullary neoplasms also had a deleterious germline mutation. Conclusion Germline mutations in pancreatic cancer susceptibility genes are commonly identified in patients with pancreatic cancer without a significant family history of cancer. These deleterious pancreatic cancer susceptibility gene mutations, some of which are therapeutically targetable, will be missed if current family history guidelines are the main criteria used to determine the appropriateness of gene testing.
引用
- Shindo K, Yu J, Suenaga M, et al. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. J Clin Oncol. 2017. PMID: 28767289. doi:10.1200/JCO.2017.72.3502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。